ArticleBioengineering (Basel, Switzerland)2026
Biodegradable Temporizing Matrix for Facial Reconstruction Following Mohs Micrographic Surgery: A Multi-Subunit Analysis.
Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiodegradable Temporizing Matrix (BTM) is a synthetic, biodegradable polyurethane dermal substitute that promotes neodermis formation and supports re-epithelialization by secondary intention. However, published experience with BTM in facial reconstruction is limited to small case series with narrow anatomic indications, and its performance across multiple distinct facial subunits has not been systematically characterized.
methodsA retrospective case series was conducted of all patients who underwent nasal, periocular, or scalp reconstruction with BTM following Mohs micrographic surgery (MMS) at a single tertiary academic center. Patient demographics, defect characteristics, healing times, complications, and secondary procedures were recorded.
resultsA total of 135 patients were included: 67 nasal, 40 periocular, and 28 scalp. Overall complication rates were 7.5%, 20.0%, and 17.9%, respectively. The majority of patients across all sites achieved definitive coverage by secondary intention without skin grafting. Lower eyelid involvement was the strongest independent predictor of ocular complications in the periocular cohort, and prior radiation was the dominant predictor of scalp complications.
conclusionsIn this retrospective series, BTM demonstrated favorable outcomes for facial reconstruction following MMS across nasal, periocular, and scalp subunits, reliably supporting secondary re-epithelialization and functioning as definitive reconstruction, a temporizing agent, and a lining adjunct for staged forehead flap reconstruction. Prospective comparative studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.